Chris provides operational and scientific oversight of the activities of the Conrad Prebys Center for Chemical Genomics.
Chris received his Ph.D. at Harvard University and his postdoctoral training at UC Berkeley.
View All Publications
Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models.
Bonnefous C, Payne JE, Roppe J, Zhuang H, Chen X, Symons KT, Nguyen PM, Sablad M, Rozenkrants N, Zhang Y, Wang L, Severance D, Walsh JP, Yazdani N, Shiau AK, Noble SA, Rix P, Rao TS, Hassig CA, Smith ND
J Med Chem. 2009 May 14;52(9):3047-62
KLYP956 is a non-imidazole-based orally active inhibitor of nitric-oxide synthase dimerization.
Symons KT, Massari ME, Nguyen PM, Lee TT, Roppe J, Bonnefous C, Payne JE, Smith ND, Noble SA, Sablad M, Rozenkrants N, Zhang Y, Rao TS, Shiau AK, Hassig CA
Mol Pharmacol. 2009 Jul;76(1):153-62
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Payne JE, Jenkins DA, Bonnefous C, Trotter C, Wang Y, Anzola JV, Milkova EL, Hoffman TZ, Dozier SJ, Wiley BM, Saven A, Malecha JW, Davis RL, Muhammad J, Shiau AK, Noble SA, Rao TS, Smith ND, Hager JH
Mol Cancer Ther. 2008 May;7(5):1054-65
Inhibition of inducible nitric oxide synthase expression by a novel small molecule activator of the unfolded protein response.
Symons KT, Massari ME, Dozier SJ, Nguyen PM, Jenkins D, Herbert M, Gahman TC, Noble SA, Rozenkrants N, Zhang Y, Rao TS, Shiau AK, Hassig CA
Curr Chem Genomics. 2008;2:1-9
Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex.
Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL
Nature. 1998 Oct 29;395(6705):917-21
Histone deacetylase activity is required for full transcriptional repression by mSin3A.
Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE
Cell. 1997 May 2;89(3):341-7
A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p.
Taunton J, Hassig CA, Schreiber SL
Science. 1996 Apr 19;272(5260):408-11
Christian Hassig's Research Focus
Chris provides operational and scientific oversight of the activities of the Conrad Prebys Center for Chemical Genomics. Additionally, Chris functions as Sanford-Burnham’s Scientific Coordinator for NCI’s Chemical Biology Consortium (NCI-CBC) as well as industry and academic outreach programs outside of the NIH Roadmap.
Chris brings to the position experiences that include innovative small-molecule drug identification, lead optimization and preclinical development, and coordination of multidisciplinary research teams.
About Christian Hassig
Chris received his Ph.D. in Professor Stuart Schreiber’s laboratory at Harvard University and completed his postdoctoral training at UC Berkeley under the supervision of Dr. Barbara Meyer. Most recently, Chris served as Associate Director of Biology at Kalypsys, Inc., a privately owned biopharmaceutical company specializing in small molecule drug discovery and development. During his tenure in industry, he designed and coordinated the execution of numerous HTS campaigns against various targets, including deacetylases, kinases, and nitric oxide synthases. In addition, he directed three projects to Investigational New Drug (IND) stage, and one through completion of Phase II clinical trials. This research also led to a number of peer-reviewed scientific articles describing the biological, chemical and pharmacological properties of novel small molecule modulators of these targets. Chris also holds an adjunct faculty appointment at The Scripps Research Institute in La Jolla.